Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant

NCT04425226 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Liver Transplant; Complications
Hepatocellular Carcinoma Recurrent

Interventions

DRUG: Pembrolizumab Injection [Keytruda]
DRUG: Lenvatinib Oral Product

Sponsor

RenJi Hospital